Home » Venture Capital » Current Portfolio

Current Portfolio

Flagship invests in three principle business sectors: Therapeutics; Health Technologies; and Sustainability/Clean Technology. Initial investments range between $250 thousand and $5 million, and we may invest up to $12-15 million during the life of a company. Click on a tab below to filter the listing of the portfolio by industry sector, or on a column heading to sort.

Companysort icon Description Status Initial Date
<a href="/venture-capital/all-companies/acceleron-pharma-inc">Acceleron Pharma, Inc.</a> Discovering, developing, manufacturing and commercializing novel protein therapeutics for orphan diseases and cancer. Private 2004 View Profile
<a href="/venture-capital/all-companies/aerodesigns-inc">AeroDesigns Inc.</a> Pioneering air-based delivery systems to reimagine the consumption of food, nutrients and medications. Private 2011 View Profile
<a href="/venture-capital/all-companies/affinnova-inc">Affinnova, Inc.</a> Pioneering evolutionary algorithms for marketing content optimization. Private 2000 View Profile
<a href="/venture-capital/all-companies/agios-pharmaceuticals-inc">Agios Pharmaceuticals, Inc.</a> Discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. Private 2007 View Profile
<a href="/venture-capital/all-companies/avedro-inc">Avedro, Inc.</a> Developing incisionless vision correction procedures. Private 2009 View Profile
<a href="/venture-capital/all-companies/bg-medicine-inc">BG Medicine, Inc.</a> Novel diagnostics to improve patient outcomes and contain healthcare costs. Public 2000 View Profile
<a href="/venture-capital/all-companies/bind-therapeutics-inc">BIND Therapeutics, Inc.</a> Developing a new class of highly selective targeted and programmable therapeutics called Accurins™. Private 2007 View Profile
<a href="/venture-capital/all-companies/black-duck-software-inc">Black Duck Software, Inc.</a> Provides products and services for automating the management, governance and secure use of open source software in multi-source development at enterprise scale. Private 2004 View Profile
<a href="/venture-capital/all-companies/blend-therapeutics-inc">Blend Therapeutics Inc.</a> Discovering new classes of medicines that have unique modes of action to result in drugs with differentiated therapeutic properties. Private 2012 View Profile
<a href="/venture-capital/all-companies/celexion-llc">Celexion LLC</a> Developing powerful platform technologies and products for partners in the pharmaceutical, industrial, agricultural, and consumer sectors. Private 2009 View Profile
<a href="/venture-capital/all-companies/concert-pharmaceuticals-inc">Concert Pharmaceuticals, Inc.</a> Applying the company’s DCE Platform® (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Private 2006 View Profile
<a href="/venture-capital/all-companies/eleven-biotherapeutics-inc">Eleven Biotherapeutics, Inc.</a> Creating novel and differentiated biotherapeutics: first-of-a-kind protein-based drugs. Private 2008 View Profile
<a href="/venture-capital/all-companies/ensemble-therapeutics-corporation">Ensemble Therapeutics Corporation</a> Deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Private 2004 View Profile
<a href="/venture-capital/all-companies/helicos-biosciences-corporation">Helicos BioSciences Corporation</a> Innovative genetic analysis technologies for the development and marketing of molecular diagnostics tests. Public 2003 View Profile
<a href="/venture-capital/all-companies/joule-unlimited-inc">Joule Unlimited, Inc.</a> Pioneering the production of Liquid Fuel from the Sun™. Private 2007 View Profile
<a href="/venture-capital/all-companies/ls9-inc">LS9, Inc.</a> Developing patent-pending UltraClean™ fuels and sustainable chemicals made with the power of synthetic biology. Private 2005 View Profile
<a href="/venture-capital/all-companies/mascoma-corporation">Mascoma Corporation</a> Developing environmentally sustainable, low cost, low carbon biofuels from cellulosic biomass. Private 2006 View Profile
<a href="/venture-capital/all-companies/medidametrics-inc">MedidaMETRICS, Inc.</a> Dedicated to improving healthcare performance and clinical quality Private 2010 View Profile
<a href="/venture-capital/all-companies/midori-renewables-inc">Midori Renewables Inc.</a> Commercializing chemical catalysts for upgrading waste biomass to fuels, chemicals, and materials. Private 2010 View Profile
<a href="/venture-capital/all-companies/moderna">moderna</a> Pioneering an entirely new drug modality using messenger RNA therapeutics™. Private 2010 View Profile